Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 307-312

  Imig, John D ^a   Pham, Bao Thang ^a   LeBlanc, Elizabeth A ^a   Reddy, K Malla ^b   Falck, John R ^b   Inscho, Edward W ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase; Cytochrome P450; Cytosolic calcium; Endothelin 1; Microcirculation; Renal hemodynamics

Indexed keywords

ARACHIDONIC ACID; CALCIUM; CYTOCHROME P450; ENDOTHELIN 1; PROSTAGLANDIN SYNTHASE;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DIAMETER; CALCIUM CELL LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

EID: 0343820031     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.307     Document Type: Conference Paper

References (32)

1. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol. 1998;32:S2-S13.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J. 1995;9:1196-1204.
4. Pinto-Sietsma SJ, Paul M. A role for endothelin in the pathogenesis of hypertension: Fact or Fiction? Kidney Int. 1998;54:S115-S121.
5. Noll G, Wenzel RR, Lüscher TF. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem. 1996;157:259-267.
6. Oyekan AO, McAward K, Conetta J, Rosenfeld L, McGiff JC. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol. 1999;276: R766-R775.
7. Oyekan AO, McGiff JC. Cytochrome P-450 derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am J Physiol. 1998;274:R52-R61.
8. Cairns HS, Rogerson ME, Fairbanks LD, Neild GH, Westwick J. Endothelin induces an increase in renal vascular resistance and a fall in glomerular filtration rate in the rabbit isolated perfused kidney. Br J Pharmacol. 1989;98:155-160.
9. Gonzalez MR, Villa E, Garcia-Robles R, Angulo J, Peiro C, Marin J, Sanchez-Ferrer CF. Effects of indomethacin and iloprost on contraction of afferent arterioles by endothelin-1 in juxtamedullary nephron preparations from normotensive Wistar-Kyoto and spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1996;28:809-816.
10. Munger KA, Takahashi K, Awazu M, Frazer M, Falk SA, Conger JD, Badr KF. Maintenance of endothelin-induced renal arteriolar constriction in rats is cyclooxygenase dependent. Am J Physiol. 1993;264:F637-F644.
11. Takenaka T, Forster H, Epstein M, Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin. Circ Res. 1993;73:743-750.
12. B receptor-mediated constriction in the renal microcirculation of rats. J Physiol. 1996;497:211-218.
13. Loutzenhiser R, Epstein M, Hayashi K, Horton C. Direct visualization of effects of endothelin on the renal microvasculature. Am J Physiol. 1990; 258:F61-F68.
14. Douglas SA, Ohlstein EH. Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res. 1997;34:152-164.
15. 2+-dependent pathway. Am J Physiol. 1996;271: C869-C877.
16. Oyeken A, Balazy M, McGiff JC. Renal oxygenases: differential contribution to vasoconstriction induced by ET-1 and Ang II. Am J Physiol. 1997;273:R293-R300.
17. 2 and modulation by lipoxygenase and P-450 pathways. Am J Physiol. 1997;273:F274-F282.
18. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther. 1998;284:966-973.
19. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol. 1999;127:1399-1405.
20. Inscho EW, LeBlanc EA, Pham BT, White SM, Imig JD. Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension. 1999;33:195-200.
21. 2 in rat renal medullary interstitial cells. Am J Physiol. 1994;266:F46-F56.
22. Chou SY, Porush JG. Renal actions of endothelin-1 and endothelin-3: interactions with the prostaglandin system and nitric oxide. Am J Kidney Dis. 1995;26:116-123.
23. Lin H, Smith MJ, Young DB. Roles of prostaglandins and nitric oxide in the effect on endothelin-1 on renal hemodynamics. Hypertension. 1996; 28:372-378.
24. Lin L, Nasjletti A. Prostanoid-mediated vascular contraction in normotensive and hypertensive rats. Eur J Pharmacol. 1992;220:49-53.
25. Gordienko DV, Clausen C, Goligorsky MS. Ionic currents and endothelin signaling in smooth muscle cells from rat renal resistance arteries. Am J Physiol. 1994;266:F325-F341.
26. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 1996;270:R217-R227.
27. Ma YH, Gebremedhin D, Schwartzman ML, Falck JR, Clark JE, Masters BS, Harder DR, Roman RJ. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res. 1993; 72:126-136.
28. Gebremedhin D, Lange AR, Narayanan J, Aebly MR, Jacobs ER, Harder DR. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca current. J Physiol. 1998;507:771-781.
29. Hayashi K, Loutzenhiser R, Epstein M. Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole. J Am Soc Nephrol. 1997;8:25-31.
30. Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW. Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension. 2000;35(pt 2):280-286.
31. Carroll MA, Garcia MP, Falck JR, McGiff JC. Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites. J Pharmacol Exp Ther. 1992;260:104-109.
32. McGiff JC, Quilley J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol. 1999;277:R607-R623.